Literature DB >> 24681912

High-potency statins increase the risk of acute kidney injury: evidence from a large population-based study.

Giovanni Corrao1, Davide Soranna2, Manuela Casula3, Luca Merlino4, Maria Gabriella Porcellini5, Alberico L Catapano6.   

Abstract

OBJECTIVE: To assess the association between acute kidney injury and exposure to either high-potency statins or low-potency statins.
DESIGN: A population-based, nested case-control study was performed on a cohort of 316,449 patients from Lombardy (Italy) newly treated with statins between 2007 and 2010 aged 40 years or older. 458 patients experienced acute kidney injury within six months after initial statin prescription. Up to four controls were randomly selected for each case. Logistic regression was used to model the outcome risk associated with high-potency contrasted with low-potency statins dispensed at starting therapy, and during follow-up.
RESULTS: Patients at whom high-potency statins were initially dispensed were more likely to be hospitalized for acute kidney injury within six months after starting treatment than those on low-potency statins (adjusted OR 1.54, 95% confidence interval 1.25-1.91). Patients receiving high-potency statins within three weeks before the outcome onset had a significant increased risk respect to those who did not receive statins during the same time-window (adjusted OR 1.45, 95% confidence interval 1.04-2.03). When follow-up was extended from 6 months to 12 months the difference was not significant anymore (adjusted OR 1.17, 95% confidence interval 0.89-1.54).
CONCLUSIONS: Use of high-potency statins is associated with an increased risk of acute kidney injury compared with low-potency statins in the first 6 months after starting therapy.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Databases; Drug safety; High-potency; Kidney injury; Low-potency; Nested case-control study; Statins

Mesh:

Substances:

Year:  2014        PMID: 24681912     DOI: 10.1016/j.atherosclerosis.2014.02.022

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  4 in total

1.  Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study.

Authors:  Lianne Parkin; Katrina J Sharples; David J Barson; Mei-Ling Blank
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

2.  Formal comment on "Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease".

Authors:  David M Diamond; Michel de Lorgeril; Malcolm Kendrick; Uffe Ravnskov; Paul J Rosch
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

3.  Intensity of statin therapy and renal outcome in chronic kidney disease: Results from the Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease.

Authors:  Jong Hyun Jhee; Young Su Joo; Jung Tak Park; Tae-Hyun Yoo; Sue Kyung Park; Ji Yong Jung; Soo Wan Kim; Yun Kyu Oh; Kook-Hwan Oh; Shin-Wook Kang; Kyu Hun Choi; Curie Ahn; Seung Hyeok Han
Journal:  Kidney Res Clin Pract       Date:  2020-03-31

4.  Statins ameliorate cholesterol-induced inflammation and improve AQP2 expression by inhibiting NLRP3 activation in the kidney.

Authors:  Yonglun Kong; Weijing Feng; Xiaoduo Zhao; Puhua Zhang; Suchun Li; Zhijian Li; Yu Lin; Boen Liang; Chunling Li; Weidong Wang; Hui Huang
Journal:  Theranostics       Date:  2020-08-20       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.